212 related articles for article (PubMed ID: 15377175)
1. Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?
Vianna-Jorge R; Suarez-Kurtz G
BioDrugs; 2004; 18(5):329-41. PubMed ID: 15377175
[TBL] [Abstract][Full Text] [Related]
2. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
3. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
4. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
Rauer H; Pennington M; Cahalan M; Chandy KG
J Biol Chem; 1999 Jul; 274(31):21885-92. PubMed ID: 10419508
[TBL] [Abstract][Full Text] [Related]
5. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
[TBL] [Abstract][Full Text] [Related]
6. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
7. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K(+) channels.
Rauer H; Lanigan MD; Pennington MW; Aiyar J; Ghanshani S; Cahalan MD; Norton RS; Chandy KG
J Biol Chem; 2000 Jan; 275(2):1201-8. PubMed ID: 10625664
[TBL] [Abstract][Full Text] [Related]
9. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
10. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
11. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
12. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
Toldi G; Treszl A; Pongor V; Gyarmati B; Tulassay T; Vásárhelyi B
Int Immunol; 2010 Sep; 22(9):769-74. PubMed ID: 20601376
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
Toldi G; Stenczer B; Treszl A; Kollár S; Molvarec A; Tulassay T; Rigó J; Vásárhelyi B
Am J Reprod Immunol; 2011 Feb; 65(2):154-63. PubMed ID: 20649894
[TBL] [Abstract][Full Text] [Related]
14. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.
Jensen BS; Hertz M; Christophersen P; Madsen LS
Expert Opin Ther Targets; 2002 Dec; 6(6):623-36. PubMed ID: 12472376
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
Ghanshani S; Wulff H; Miller MJ; Rohm H; Neben A; Gutman GA; Cahalan MD; Chandy KG
J Biol Chem; 2000 Nov; 275(47):37137-49. PubMed ID: 10961988
[TBL] [Abstract][Full Text] [Related]
16. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.
Panyi G; Possani LD; Rodríguez de la Vega RC; Gáspár R; Varga Z
Curr Pharm Des; 2006; 12(18):2199-220. PubMed ID: 16787250
[TBL] [Abstract][Full Text] [Related]
17. Biophysical and pharmacological aspects of K+ channels in T lymphocytes.
Panyi G
Eur Biophys J; 2005 Aug; 34(6):515-29. PubMed ID: 16184309
[TBL] [Abstract][Full Text] [Related]
18. Calcium influx kinetics, and the features of potassium channels of peripheral lymphocytes in primary Sjögren's syndrome.
Legány N; Toldi G; Orbán C; Megyes N; Bajnok A; Balog A
Immunobiology; 2016 Nov; 221(11):1266-72. PubMed ID: 27346388
[TBL] [Abstract][Full Text] [Related]
19. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers].
Devaux J; Beeton C; Béraud E; Crest M
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S16-27. PubMed ID: 15269656
[TBL] [Abstract][Full Text] [Related]
20. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
